148 related articles for article (PubMed ID: 14716750)
1. Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine.
Levi M; DeRemer SJ; Dou C; Ensminger WD; Smith DE
Biopharm Drug Dispos; 2004 Jan; 25(1):27-35. PubMed ID: 14716750
[TBL] [Abstract][Full Text] [Related]
2. Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model.
Symon Z; Levi M; Ensminger WD; Smith DE; Lawrence TS
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):473-8. PubMed ID: 11380236
[TBL] [Abstract][Full Text] [Related]
3. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys.
Bachy CM; Fazenbaker CA; Kifle G; McCarthy MP; Cassatt DR
Oncology; 2004; 67(3-4):187-93. PubMed ID: 15557777
[TBL] [Abstract][Full Text] [Related]
4. Blood thiols following amifostine and mesna infusions, a pediatric oncology group study.
Souid AK; Fahey RC; Aktas MK; Sayin OA; Karjoo S; Newton GL; Sadowitz PD; Dubowy RL; Bernstein ML
Drug Metab Dispos; 2001 Nov; 29(11):1460-6. PubMed ID: 11602522
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2002 Dec; 29(6 Suppl 19):2-8. PubMed ID: 12577236
[TBL] [Abstract][Full Text] [Related]
6. Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238
[TBL] [Abstract][Full Text] [Related]
7. Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys.
Levi M; Knol JA; Ensminger WD; DeRemer SJ; Dou C; Lunte SM; Bonner HS; Shaw LM; Smith DE
Drug Metab Dispos; 2002 Dec; 30(12):1425-30. PubMed ID: 12433814
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):794-802. PubMed ID: 14529786
[TBL] [Abstract][Full Text] [Related]
9. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
Shaw LM; Bonner HS; Brown DQ
Drug Metab Dispos; 1994; 22(6):895-902. PubMed ID: 7895607
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of spontaneous metastases formation by amifostine.
Grdina DJ; Kataoka Y; Murley JS; Hunter N; Weichselbaum RR; Milas L
Int J Cancer; 2002 Jan; 97(2):135-41. PubMed ID: 11774255
[TBL] [Abstract][Full Text] [Related]
11. Hypotensive mechanisms of amifostine.
Ryan SV; Carrithers SL; Parkinson SJ; Skurk C; Nuss C; Pooler PM; Owen CS; Lefer AM; Waldman SA
J Clin Pharmacol; 1996 Apr; 36(4):365-73. PubMed ID: 8728352
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of amifostine and its metabolites in patients.
Korst AE; Eeltink CM; Vermorken JB; van der Vijgh WJ
Eur J Cancer; 1997 Aug; 33(9):1425-9. PubMed ID: 9337685
[TBL] [Abstract][Full Text] [Related]
13. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies.
Capizzi R
Semin Oncol; 1996 Aug; 23(4 Suppl 8):2-17. PubMed ID: 8783661
[TBL] [Abstract][Full Text] [Related]
14. Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure.
Cassatt DR; Fazenbaker CA; Bachy CM; Kifle G; McCarthy MP
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):901-7. PubMed ID: 15708273
[TBL] [Abstract][Full Text] [Related]
15. Feasibility study of the pharmacology of local application of amifostine (WR-2721) to the buccal mucosa in guinea pigs.
Li C; Wang S; Huang T; Chen N; Ou M
Pharmacology; 2013; 91(5-6):281-6. PubMed ID: 23736649
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721.
Utley JF; Seaver N; Newton GL; Fahey RC
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1525-8. PubMed ID: 6090355
[TBL] [Abstract][Full Text] [Related]
17. Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration.
Ranganathan K; Simon E; Lynn J; Snider A; Zhang Y; Nelson N; Donneys A; Rodriguez J; Buchman L; Reyna D; Lipka E; Buchman SR
Pharm Res; 2018 Mar; 35(5):99. PubMed ID: 29556791
[TBL] [Abstract][Full Text] [Related]
18. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721.
Calabro-Jones PM; Fahey RC; Smoluk GD; Ward JF
Int J Radiat Biol Relat Stud Phys Chem Med; 1985 Jan; 47(1):23-7. PubMed ID: 2982751
[TBL] [Abstract][Full Text] [Related]
19. Enteral Activation of WR-2721 Mediates Radioprotection and Improved Survival from Lethal Fractionated Radiation.
Molkentine JM; Fujimoto TN; Horvath TD; Grossberg AJ; Garcia CJG; Deorukhkar A; de la Cruz Bonilla M; Lin D; Samuel ELG; Chan WK; Lorenzi PL; Piwnica-Worms H; Dantzer R; Tour JM; Mason KA; Taniguchi CM
Sci Rep; 2019 Feb; 9(1):1949. PubMed ID: 30760738
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro.
Dorr RT; Lagel K; McLean S
Eur J Cancer; 1996; 32A Suppl 4():S21-5. PubMed ID: 8976818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
